Aster DM Healthcare Ltd

- Capital expenditures for Q1 FY24 were INR 119 crores. - Expansion includes opening 25 Zest pharmacy stores over the next 2 years. - Saudi pharmacies are on track to start operations by October 2023. - Addition of 2 new hospitals, 24 pharmacies, and 6 clinics in GCC in the previous year, focused on increasing utilization this year. - O&M asset-light strategy added 530 beds in less than 2 years, including the new Aster PMF Hospital in Kollam, Kerala, which started operations in August 2023. - Ongoing projects include expansion of existing hospitals with 100 beds each added at Aster MIMS Kannur and Aster Medcity Kochi. - Pipeline includes new hospitals with 200 beds at Kasargod, 350 beds at Aster Capital Hospital Trivandrum Phase I, and 275 beds at Aster Whitefield Hospital Phase II. - Plans for tertiary and quaternary care facilities in Dubai including robotic surgery and transplants. - Commissioning of state-of-the-art 126-bed Medcare Royal Specialty Hospital in Al Qusais expected by Q4 FY24.

- Consolidated revenue grew 21% YoY to INR 3,215 crores in Q1 FY24, driven by bed expansions and increased ARPOB. - India business revenue up 29% YoY to INR 838 crores; EBITDA increased 47% YoY. - GCC business revenue grew 18% YoY to INR 2,377 crores, with core business growth at 22% excluding COVID-related revenue. - GCC pharmacy revenue increased 24% YoY, driven by digital initiatives and omni-channel engagement. - Aster Lab India expected to breakeven by end of next quarter, indicating growth potential. - Pharmacy business focusing on ecosystem consolidation, aiming to breakeven by early H1 or H2 next year before possible expansion. - Expansion plans include new hospitals and pharmacy stores (e.g., 25 Zest pharmacy stores in 2 years). - Digital initiatives (InstaGP, tele-calling) expected to contribute to incremental revenues, especially in GCC. - Non-prescription orders in GCC pharmacy surged over 35% in Q1 FY24, boosting monthly revenue by 30%.

- India operations show robust growth with revenues up 29% YoY and EBITDA increasing 47% in Q1 FY24; PAT growth at 115% YoY, indicating strong profitability momentum. - ARPOB (Average Revenue per Occupied Bed) is growing at about 8-10% annually, driven by a higher cash-payer mix (58-60%), expanding occupancy, and focus on high-end quaternary care. - Occupancy rates improving, with July occupancy reaching 68%, signaling potential for continued revenue growth. - Aster Labs India expects to achieve EBITDA breakeven by end of FY24, suggesting expanding profitability in diagnostic services. - GCC operations demonstrate 18% revenue growth YoY and 33% EBITDA growth; adjusted PAT post non-recurring items grew 57%. - New hospital expansions and digital initiatives (telemedicine, omni-channel engagement) are expected to support profitable growth. - Overall, adjusted PAT post-NCI shows an 87% growth in Q1 FY24 YoY, reflecting strong earnings growth expectations.

The transcript provided does not explicitly mention details regarding the current or expected order book or pending orders for Aster DM Healthcare Limited for Q1 FY24. However, some relevant points that may indirectly relate to future business prospects include: - Expansion plans in India with new facilities under development, including 200 beds at Aster Hospital Kasargod, 350 beds in Phase-I of Aster Capital Hospital Trivandrum, and 275 beds in Phase-II of Aster Whitefield Hospital, Bangalore. - The company is progressing with expansions at Aster MIMS and Aster Medcity by adding 100 beds each. - GCC business is expanding with new hospitals, pharmacies, and clinics added in the last fiscal year; plans for more tertiary and quaternary care treatments and new bed additions are underway. - The GCC region expects demand for over 12,000 new hospital beds by 2027, indicating growth opportunities. - Mention of ongoing restructuring and discussions with bidders indicates strategic initiatives underway but no specifics on order books. No specific figures on order books or pending orders were disclosed in the transcript.

- The transcript does not explicitly mention any current or upcoming fundraising through debt or equity. - There is no direct discussion on plans for raising capital via debt or equity in the provided Q1 FY24 earnings call excerpts. - The company is focusing on consolidation and stabilizing operations, especially in pharmacy and lab businesses, rather than aggressive expansion requiring new fundraising. - Capital expenditures for the quarter were INR 119 crores, sourced from operational cash flow or existing resources, with no mention of external fundraising. - The restructuring of the GCC business is ongoing but does not specify fundraising through debt or equity.